Modality
Degrader
MOA
FGFRi
Target
EGFR
Pathway
Neuroinflam
MigraineOvarian CaCeliac
Development Pipeline
Preclinical
~Mar 2021
→ ~Jun 2022
Phase 1
~Sep 2022
→ ~Dec 2023
Phase 2
~Mar 2024
→ ~Jun 2025
Phase 3
Sep 2025
→ Feb 2029
Phase 3Current
NCT06769352
2,906 pts·Ovarian Ca
2025-09→2029-02·Not yet recruiting
2,906 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-062.9y awayPh3 Readout· Ovarian Ca
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P3
Not yet…
Catalysts
Ph3 Readout
2029-02-06 · 2.9y away
Ovarian Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06769352 | Phase 3 | Ovarian Ca | Not yet recr... | 2906 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR | |
| Capicilimab | Structure Ther | Phase 1 | EGFR |